EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the recommended first-line therapy for patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) [1,2]. The prevalence of EGFR mutations in NSCLC is 11 –17% in Western patients and 36–54% in Asian patients [1,3–9]. Among patients with EGFR mutations, the most common types are exon 19 deletion (ex19del) and L858R, representing ~90% of EGFR mutations, and conferring sensitivity to EGFR-TKIs [1,10]. Despite high response rates, more than 50% of patients treated in the first-line with a first- or second-generation EGFR-TKI develop resistance due to the occurrence of the EGFR T790 M resistance mutation [11–13].

Source: Lung Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Thomas John, Hiroaki Akamatsu, Angelo Delmonte, Wu-Chou Su, Jong Seok Lee, Gee-Chen Chang, Xiangning Huang, Suzanne Jenkins, Yi-Long Wu Source Type: research